Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 17, 2014 Athena Signature Series: Turning Cancer ... Beverly Emerson, a professor in the Regulatory Biology Laboratory at ... recent discovery points to an “off switch” for drug resistance ... how her local research is making a global impact in ... and then join host Cheryl K. Goodman, CEO of Social ...
(Date:11/18/2014)... Texas (PRWEB) November 18, 2014 ... Polytetrahydrofuran (PTMEG) Industry is professional and in-depth ... gives Polytetrahydrofuran basic information, including its definition, ... also industry outline. This exploration covers the ... and worldwide industry examination covering macroeconomic environment ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... Multiporator , , , , , , , , ... Protocol No. 4308 915.029 11/1999 , , , , , ... , Cell line , 293 T, human embryonal kidney, ... Plasmid pEGFP-N1 (in bidistilled H 2 O), , ...
... , , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.541 03/2002 , ... , , , , ... , Cell type , Bacteria, gram positive, ...
... Electroporator 2510 , , , , , , , , ... Protocol No. 4308 915.534 01/2002 , , , , ... , Microorganism , Staphylococcus epidermidis, ... Bacteria, gram positive, , , ...
Cached Biology Technology:293 T 2Streptococcus salivarius 2Staphylococcus epidermidis 2
(Date:11/4/2014)... School of Medicine announced today that it is ... by the Bill & Melinda Gates Foundation. ... and Reproductive Sciences; and Vice Chair of Research ... Medicine will pursue an innovative global health and ... Assess Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds ...
(Date:11/4/2014)... examining only marketing directed at children on the ... found that the majority of black, middle-income and ... tactics. , Authored by Arizona State University researcher ... the first to examine the use of child-directed ... food restaurants and its relationship to demographics. It ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... calls for policymakers to reduce both nitrogen and phosphorus ... problems in fresh and coastal waters. In the ... argue that dual-nutrient reduction strategies are likely to be ... phosphorus in fresh and coastal water ecosystems. "If ...
... 2009 ― Protecting drinking water and preventing harmful ... many lakes, will require reducing both nitrogen and ... to the sea, management strategies should be implemented ... that focus only on one nutrient will fail. ...
... be exhausting. When fruit flies mate, the females, genes ... an immune reaction starts. This is shown in a ... the scientific publication, Journal of Evolutionary Biology .* ... genomic technology, so-called microarrays, researchers at Uppsala University can ...
Cached Biology News:Nutrient pollution chokes marine and freshwater ecosystems 2
... sufficient materials for 1,464 array sample elements. , , ... , Blocker BSA in PBS (10X): 50 ml ... BupH Phosphate Buffered Saline: 8 packs , 10% ... Pico Luminol Enhancer: 2 x 25 ml , SuperSignal ...
... The Partec Cell Counter Analyser counts cells ... the CCA detects only cells, so that ... the results.,While passing through a 250 m ... fluorescence light signal which is used as ...
... Obtain Clean and Accurate Results ... dramatically increase the sensitivity and accuracy of ... homogeneous cell types and multi-cellular structures isolated ... unique approach to microdissection-developed in 1996 at ...
Mouse monoclonal antibody raised against a partial recombinant DHX8. NCBI Entrez Gene ID = DHX8...
Biology Products: